Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

Franck, Caspar; Canbay, Ali; Malfertheiner, Peter; Venerito, Marino

doi:10.3892/mco.2017.1445

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to surgery alone, neoadjuvant and adjuvant strategies improve the outcome of patients with locally advanced GC and adenocarcinoma of the esophagogastric junction (AEG) who receive curative‐intent surgery, both in younger and elderly patients …”

Section: Gastric Cancer: Treatmentmentioning

confidence: 99%

Gastric cancer: epidemiology, prevention, and therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) is still the third leading cause of cancer death in both sexes worldwide. Helicobacter pylori infection is the most important risk factor for GC and, in spite of the consistent trend of a decreasing incidence, in 2015 approximately 4.4 billion individuals-more than half the world's population-were infected with H. pylori. The birth cohort pattern of decreased H. pylori infection reported in a systematic review contributes to explain the declining GC mortality in Japan. Current trends in estimated annual percentage change of GC incidence foreshadow expected reversals in both falling incidence and male predominance among US non-Hispanic whites. Combining serum pepsinogen 1 and H. pylori serology was shown to be useful for GC risk stratification in a Finnish population. Gastritis staging by operative link on gastritis assessment was confirmed to be reliable in predicting GC risk in a large prospective study. In a randomized trial from South Korea, H. pylori eradication therapy significantly reduced the rates of metachronous GC in patients who received curative endoscopic resection for early GC. A study based on a territory-wide health care database of the Hong Kong Hospital Authority showed that aspirin use is associated with a reduced GC risk. Another study based on the same database showed that proton pump inhibitors increase GC risk, but methodological biases have most likely acted as confounders. Confirmatory data on the role of endoscopic submucosal dissection in patients with early GC have been published. The phase III FLOT4 trial has shown that the FLOT triplet regimen (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) improves the outcome of patients with GC and locoregional disease as compared to the ECF triplet (epirubicin, cisplatin, and 5-fluorouracil). In the phase III ATTRACTION-2 trial, nivolumab was shown to be an effective treatment option with a relative safe profile for heavily pretreated patients with advanced GC.

show abstract

Section: Gastric Cancer: Treatmentmentioning

confidence: 99%

Gastric cancer: epidemiology, prevention, and therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Discontinuation rates observed in SCOOP as a result of progressive disease (26%) were similar to those reported for patients with metastatic colorectal cancer taking capecitabine monotherapy in the above-mentioned real-world survey (up to 24%) but roughly half of what was observed in FLAGS (62%). While this might be a reflection of the real-world setting [ 8 , 21 ], a more plausible explanation for this observation is the use of S-1-based chemotherapy in a perioperative setting in which only four cycles (two each in the neoadjuvant and adjuvant settings) are foreseen [ 22 ]. The latter explanation is supported by the fact that the majority of patients included in SCOOP (66%) had locally advanced disease without distant metastasis, a clear indication for perioperative chemotherapy according to the current guidelines [ 6 , 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

Venerito

2019

Drugs R D

Self Cite

View full text Add to dashboard Cite

Background and Objectives S-1-based regimens have been shown to be as effective as other fluoropyrimidine-based regimens with a better safety profile in patients with advanced esophagogastric adenocarcinoma. However, real-world data on S-1 in European patients with advanced esophagogastric adenocarcinoma are lacking. The Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) study evaluated safety and relative dose intensities for patients treated with S-1-based regimens for advanced esophagogastric adenocarcinoma as part of daily practice. Methods Overall, data for 125 patients with advanced esophagogastric adenocarcinoma were collected at 21 centers in five countries in Europe. Demographics, treatment, and adverse-event data were recorded over a planned treatment of six cycles. Results Most patients (87%) received combination treatment of S-1 plus a platinum compound. Adverse events related to S-1 treatment were mostly grade 1 or 2 while reported grade 3–4 serious adverse events related to S-1 occurred in 12 patients and were most often grade 3 neutropenia ( n = 4, 3.2%) or diarrhea ( n = 5, 4%). The most common adverse events of any grade that were attributable to S-1 treatment included neutropenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, and fatigue. No patients experienced mucositis, dehydration, or febrile neutropenia, whereas 2% (3/125) of patients experienced hand-foot syndrome. Conclusion The overall relative dose intensity was 70%. In a real-world setting, patients with advanced esophagogastric adenocarcinoma tolerated S-1 treatment well with high compliance rates. The SCOOP study provides valuable information on S-1 relative dose intensity that can be used for treatment decision making.

show abstract

“…1A). S-1, oral fluorouracil, is a key medication for gastrointestinal malignancies (the stomach, colorectal, biliary tract, and PDAC) 24,82,83 and is approved in many Asian countries. In Europe, S-1 is also approved by the European Medicines Agency and has been used for the treatment of advanced gastric cancer combined with cisplatin.…”

Section: Practice and Development Of Perioperative Treatment For Pdac...mentioning

confidence: 99%

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan

Takahashi

Ogasawara

et al. 2023

Gut and Liver

View full text Add to dashboard Cite

Resection is the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Although the outcome of technically resectable PDAC has improved with advances in surgery and adjuvant therapy, the 5-year survival rate remains low at 20% to 40%. More effective therapy is needed. Almost 15 years ago, the National Comprehensive Cancer Network guidelines proposed a resectability classification of PDAC based on preoperative imaging. Since then, treatment strategies for PDAC have been devised based on resectability. The standard of care for resectable PDAC is adjuvant chemotherapy after R0 resection, as shown by the results of pivotal clinical trials. With regard to neoadjuvant treatment, several recent clinical trials comparing neoadjuvant treatment with upfront resection have been conducted on resectable PDAC and borderline resectable PDAC, and the benefits and efficacy of neoadjuvant treatment for pancreatic cancer has become clearer. The significance of neoadjuvant treatment for resectable PDAC remains controversial, but in borderline resectable PDAC the efficacy of neoadjuvant treatment has been further recognised, although the standard of care has not yet been established. Several promising clinical trials for PDAC are ongoing. This review presents previous and ongoing trials of perioperative treatment for resectable and borderline resectable PDAC, focusing on the difference between Asian and Western countries.

show abstract

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

Cited by 4 publications

References 25 publications

Gastric cancer: epidemiology, prevention, and therapy

Gastric cancer: epidemiology, prevention, and therapy

S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan

Contact Info

Product

Resources

About